Bioservo Technologies

Bioservo has registered the strength-enhancing glove Carbonhand as an assistive medical device in Europe, Australia, and the United States. Bioservo and the sales organizations in each market are working with high intensity to obtain market access and reimbursement from authorities and insurance companies. 

At the same time, the work is intensified to obtain MDR approval for Carbonhand as a class IIa product in Europe and class 510(k) in the United States to also be able to claim that Carbonhand has a therapeutic effect. This is possible thanks to the results of the iHand study, which demonstrated a sustained improvement in grip strength of 24%.

In the work to strengthen the company's focus on topics related to market access and clinical evidence, we are therefore pleased to present Annika Rydgård as a new member of the management team.

"Annika has a solid background as a research-oriented therapist and has for some time worked closely with the commercial team. Thanks to her clinical knowledge and positive energy, she has quickly become established and requested as a key resource in the work to deepen the knowledge of Carbonhand, our studies, and our patient groups," says Petter Bäckgren, CEO of Bioservo.

For more information, please contact,
Petter Bäckgren, CEO, Bioservo Technologies AB
Phone: +468 21 17 10
petter.backgren@bioservo.com

Mikael Wester, Marketing Director, Bioservo Technologies AB
Phone: +468 21 17 10
mikael.wester@bioservo.com

About Bioservo Technologies
Bioservo Technologies AB (publ) is a world-leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy, and efficient. The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health of workers and to improve the quality of life for people with reduced muscle strength. Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB is the company’s Certified Adviser on Nasdaq First North.
For more information, please visit www.bioservo.com